Recombinant SARS-CoV-2 Surface glycoprotein (Val16-Lys1211) [Avi-tag&His tag], CHO (CAT#: GP05-084J)

Product Overview	Recombinant 2019-nCoV/SARS-CoV-2 Surface glycoprotein (YP_009724390.1) (Val16-Lys1211) was produced in CHO cells with a Avi-tag&6-His tag at the C-terminus. Measured by its binding ability in a functional ELISA with recombinant human ACE-2.
Biological Activity	Measured by its binding ability in a functional ELISA with recombinant human ACE-2.
Source	CHO cells
Species	2019-nCoV/SARS-CoV-2
Fragment	Val16-Lys1211
Tag	Avi-tag&6-His tag at the C-terminus
Predicted N Terminal	Val16
Predicted MW	136 kDa
Purity	>95%, determined by SDS-PAGE.
Endotoxin Level	<0.1 EU/μg, determined by LAL method.
Conjugation	Biotin

Target	S
Full Name	Surface glycoprotein
Gene ID	43740568
Uniprot ID	P0DTC2
Accession Number	YP_009724390.1
Background	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). The spike glycoprotein is found on the outside of the virus particle and gives coronavirus viruses their crown-like appearance. This glycoprotein mediates attachment of the virus particle and entry into the host cell. S protein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.
Alternate Names	Spike glycoprotein